Companies › AstraZeneca
135 active drug programs in 1690 registered trials: 841 Phase 2, 385 Phase 3, 372 Phase 1, 92 Phase 4; Oncology, Other, Metabolic and endocrine, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Osimertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 4 | Non-small Cell Lung Cancer; Carcinoma; Metastatic Non-small Cell Lung Cancer; Cancer … | Nov 2026 |
| Benralizumab Interleukin-5 receptor subunit alpha inhibitor | IL5RA | Phase 4 | Asthma; Eosinophilic Asthma; Eosinophilic Granulomatous Vasculitis; Hypereosinophilic Syndrome … | Nov 2026 |
| Olaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 4 | Metastatic Castration-resistant Prostate Cancer; Advanced Ovarian Cancer; Platinum Sensitive; Endometrial Neoplasms … | Nov 2026 |
| Dapagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Chronic Kidney Disease; Heart Failure and Impaired Kidney Function; Chronic Kidney Disease and Hypertension; Type 2 Diabetes Mellitus … | Dec 2026 |
| Datopotamab Deruxtecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 4 | Stomatitis; Breast Cancer; Metastatic Non-small Cell Lung Cancer; Non-small Cell Lung Cancer … | Dec 2026 |
| Trastuzumab deruxtecan Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor | ERBB2, TOP1 | Phase 4 | BREAST CANCER; Advanced or Metastatic Breast Cancer; Breast Neoplasms; Breast Cancer; HER2-positive; Metastatic … | Dec 2026 |
| Acalabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 4 | Chronic Lymphocytic Leukaemia; Untreated Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; Mantle-cell Lymphoma … | Jan 2027 |
| Anifrolumab Interferon-alpha/beta receptor alpha chain antagonist | IFNAR1 | Phase 4 | Systemic Lupus Erythematosus; Systemic Sclerosis; Lupus Nephritis; Cutaneous Lupus Erythematosus … | Jan 2027 |
| Albuterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 4 | Asthma | Feb 2027 |
| Budesonide (PT027) Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Chronic Obstructive Pulmonary Disease; Asthma; Functional Dyspepsia; IgA Nephropathy … | May 2027 |
| Ravulizumab Complement C5 inhibitor | C5 | Phase 4 | aHUS; Generalized Myasthenia Gravis; Delayed Graft Function; NMOSD … | Jun 2027 |
| Breztri Aerosphere Triple combination: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonis | ADRB2, CHRM3 | Phase 4 | Moderate to Severe COPD | Dec 2027 |
| Capivasertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Locally Advanced (Inoperable) or Metastatic Breast Cancer; Prostate Cancer; Triple Negative Breast Neoplasms; Breast Cancer … | Nov 2026 |
| AZD0901 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Gastric Cancer | Nov 2026 |
| Elecoglipron Dipeptidyl peptidase-4 (DPP-4) inhibitor | DPP4, GCK, GCGR | Phase 3 | Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) … | Nov 2026 |
| savolitinib Hepatocyte growth factor receptor inhibitor | MET | Phase 3 | Carcinoma; Papillary Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Lung Cancer … | Nov 2026 |
| Durvalumab (MEDI4736) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 3 | Non Small Cell Lung Carcinoma NSCLC; Hepatocellular Carcinoma; Small Cell Lung Cancer; Biliary Tract Cancer … | Nov 2026 |
| Tremelimumab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 3 | Small Cell Lung Cancer; Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma; Non Small Cell Lung Carcinoma NSCLC … | Nov 2026 |
| eculizumab Complement C5 inhibitor | C5 | Phase 3 | NMOSD; Neuromyelitis Optica Spectrum Disorder Attack; Neuromyelitis Optica Spectrum Disorders (NMOSD); Hypertensive Emergency-associated Hemolytic Uremic Syndrome … | Dec 2026 |
| baxdrostat Aldosterone synthase inhibitor | CYP11B2 | Phase 3 | Primary Hyperaldosteronism; Uncontrolled Hypertension; Chronic Kidney Disease and Hypertension | Dec 2026 |
| gefurulimab CD23 antagonist monoclonal antibody | FCER2 | Phase 3 | Generalized Myasthenia Gravis | Dec 2026 |
| Bevacizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Hepatocellular Carcinoma; Advanced Ovarian Cancer; Hepatocellular Carcinoma (HCC); Keloids … | Dec 2026 |
| ceralasertib Serine-protein kinase ATR inhibitor | ATR | Phase 3 | Advanced or Metastatic Non-Small Cell Lung Cancer; Metastatic Triple Negative Breast Cancer; Melanoma; Non-Small Cell Lung Cancer … | Dec 2026 |
| Fulvestrant Estrogen receptor alpha antagonist; Estrogen receptor degrader | ESR1 | Phase 3 | Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-positive Breast Cancer; Breast Cancer Metastatic … | Dec 2026 |
| Selumetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV; Neurofibromatosis 1; Advanced Non Small Cell Lung Cancer; Tumor … | Dec 2026 |
| AZD0780 PCSK9 inhibitor | PCSK9 | Phase 3 | Heterozygous Familial Hypercholesterolaemia; Cardiovascular Disease; Dyslipidaemia | Jan 2027 |
| Eplontersen Transthyretin mRNA antisense inhibitor | TTR | Phase 3 | Transthyretin Amyloid Cardiomyopathy; Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Jan 2027 |
| Monalizumab NKG2-A/NKG2-B type II integral membrane protein inhibitor | KLRC1 | Phase 3 | Squamous Cell Carcinoma of the Head and Neck; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Acute Myeloid Leukaemia … | Jan 2027 |
| Oleclumab 5'-nucleotidase inhibitor | NT5E | Phase 3 | Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Triple Negative Breast Neoplasms … | Jan 2027 |
| Tezepelumab Thymic stromal lymphopoietin inhibitor | TSLP | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps; Eosinophilic Esophagitis; Severe Asthma; Asthma … | Jan 2027 |
| Volrustomig (MEDI5752) CTLA-4/PD-1 bispecific antibody | CTLA4, PDCD1, TIGIT | Phase 3 | Metastatic Non-small Cell Lung Cancer; Locally Advanced Cervical Cancer; Unresectable Pleural Mesothelioma; Locally Advanced Head and Neck Squamous Cell Carcinoma … | Jan 2027 |
| abiraterone acetate Cytochrome P450 17A1 inhibitor | CYP17A1 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Feb 2027 |
| Zibotentan Endothelin receptor ET-A antagonist | EDNRA | Phase 3 | Chronic Kidney Disease With High Proteinuria | Feb 2027 |
| AZD2936 (rilvegostomig) Anti-TIGIT/anti-PD-1 bispecific antibody | TIGIT, PDCD1 | Phase 3 | Non-small Cell Lung Cancer; Biliary Tract Cancer; Endometrial Cancer; HER2-positive Gastric Cancer … | Mar 2027 |
| CAEL-101 monoclonal antibody against misfolded light chain amyloid deposits | ALB | Phase 3 | AL Amyloidosis | Apr 2027 |
| Camizestrant (AZD9833) Estrogen receptor alpha degrader | ESR1 | Phase 3 | Breast Cancer, Early Breast Cancer; ER-Positive HER2-Negative Breast Cancer; Advanced Breast Cancer; Advanced ER-Positive HER2-Negative Breast Cancer … | Apr 2027 |
| Danicopan Complement factor D inhibitor | CFD | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | May 2027 |
| Rosuvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Hypercholesterolaemia; Acute Coronary Syndromes; Coronary Artery Disease; Statin Therapy … | May 2027 |
| Tozorakimab Dose Regimen 1 IL-13 receptor antagonist | IL13 | Phase 3 | Viral Lung Infection and Acute Respiratory Failure; Chronic Obstructive Pulmonary Disease; Asthma | Jun 2027 |
| eneboparatide PTH1 receptor agonist (parathyroid hormone analog) | PTH1R | Phase 3 | Chronic Hypoparathyroidism | Jun 2027 |
| Laroprovstat Small molecule reducing LDL-C | – | Phase 3 | Hypercholesterolaemia | Jul 2027 |
| ALXN1720 Complement C5 inhibitor (recombinant monoclonal antibody) | – | Phase 3 | Generalized Myasthenia Gravis | Aug 2027 |
| Puxitatug Samrotecan (AZD8205) B7-H4-targeted antibody-drug conjugate (ADC) | B7H4 | Phase 3 | Endometrial Cancer; Breast Cancer | Sep 2027 |
| Saruparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Castration-Sensitive Prostate Cancer; Advanced Breast Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer … | Sep 2027 |
| AZD0120 BCMA/CD19 dual CAR T cell therapy | BCMA, CD19 | Phase 3 | Relapsed Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Newly Diagnosed Multiple Myeloma; Relapsed/Refractory Multiple Myeloma … | Oct 2027 |
| AZD5335 Anti-FRα antibody-drug conjugate | FOLR1 | Phase 3 | Epithelial Ovarian Cancer; Fallopian Tube Cancer | Oct 2027 |
| Sonesitatug vedotin | – | Phase 3 | Gastric Cancer; Gastroesophageal Adenocarcinoma | Nov 2027 |
| BGF MDI 320/14.4/9.6 μg Triple therapy: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonist (g | ADRB2, CHRM3 | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) | Dec 2027 |
| ALXN2220 anti-TTR monoclonal antibody | TTR | Phase 3 | Transthyretin Amyloid Cardiomyopathy | Dec 2027 |
| surovatamig (AZD0486) Bispecific monoclonal antibody targeting CD20 and CD3E | CD19, CD3E, CD20 | Phase 3 | Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma … | Jan 2028 |
| ALXN1850 Alkaline phosphatase enzyme replacement therapy | ALPL | Phase 3 | Hypophosphatasia | Feb 2028 |
| Torvutatug samrotecan | – | Phase 3 | Platinum-sensitive Relapsed Epithelial Ovarian Cancer; Epithelial Ovarian Cancer; Ovarian Cancer | Aug 2028 |
| AZD6234 (Lenbelintide) Glucagon receptor agonist | GCGR | Phase 3 | Obesity or Overweight | Aug 2028 |
| Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) alpha-emitting radioimmunotherapy targeting PSMA (Folate Hydrolase 1), anti-PSMA targeting | FOLH1 | Phase 3 | Metastatic Castration-resistant Prostate Cancer; Metastatic Prostate Cancer | Jun 2029 |
| Sodium Zirconium Cyclosilicate (SZC) Selective potassium binder | – | Phase 3 | Hyperkalaemia | Feb 2030 |
| Esomeprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Erosive Esophagitis; Liver Cirrhosis; Helicobacter Pylori Infections; Radiation Esophagitis … | – |
| AZD0171 Mechanism unclear | – | Phase 2 | Locally Advanced or Metastatic Solid Tumours; Non-small Cell Lung Cancer | Nov 2026 |
| Adavosertib (AZD1775) Serine/threonine-protein kinase WEE1 inhibitor | WEE1 | Phase 2 | Metastatic Triple Negative Breast Cancer; Muscle Invasive Bladder Cancer; Prostate Cancer; Advanced Lymphoma … | Nov 2026 |
| AZD2811 Aurora B kinase inhibitor | – | Phase 2 | Small-Cell Lung Cancer | Dec 2026 |
| AZD6234 in combination with AZD9550 Dual GCG and GLP-1 receptor agonist | GCG, GLP1R | Phase 2 | Obesity/Overweight; Healthy Participants; Overweight and Obesity; Hepatic Impairment | Jan 2027 |
| AZD4144 | – | Phase 2 | Sepsis; Healthy | Feb 2027 |
| AZD5148 monoclonal antibody | – | Phase 2 | Clostridioides Difficile Infection | Apr 2027 |
| AZD7798 | – | Phase 2 | Moderate to Severe Crohn's Disease; Crohn's Disease | May 2027 |
| ALXN1920 Factor D inhibitor | – | Phase 2 | Primary Membranous Nephropathy | Jul 2027 |
| AZD2389 FAP inhibitor | FAP | Phase 2 | Liver Fibrosis | Jul 2027 |
| AZD6793 | – | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | Aug 2027 |
| AZD2373 APOL1-mediated kidney disease inhibitor | APOL1 | Phase 2 | APOL1-Mediated Kidney Disease | Oct 2027 |
| ALXN2030 | – | Phase 2 | Antibody-Mediated Rejection; Healthy | Oct 2027 |
| Tarperprumig (ALXN1820) C5a receptor antagonist | – | Phase 2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Oct 2027 |
| AZD1163 | – | Phase 2 | Rheumatoid Arthritis | Nov 2027 |
| AZD0292 bispecific IgG1k monoclonal antibody | – | Phase 2 | Bronchiectasis With Pseudomonas Aeruginosa Colonization | Dec 2027 |
| Atirmociclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Advanced Breast Cancer | Dec 2027 |
| AZD8965 | – | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | Sep 2028 |
| Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma; Rheumatoid Arthritis (RA); ANCA Associated Vasculitis … | Oct 2028 |
| ALXN2220 Factor D complement inhibitor | CFD | Phase 2 | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Feb 2029 |
| Glycopyrronium Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor | CHRM3, CHRM1, CHRM4, CHRM2, CHRM5 | Phase 2 | Asthma | May 2029 |
| Danvatirsen STAT-3 mRNA 3'UTR antisense inhibitor | STAT3 | Phase 2 | Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced Colorectal Carcinoma; AML/MDS | – |
| Necitumumab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Non-Small Cell Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma | – |
| Vistusertib Serine/threonine-protein kinase mTOR inhibitor | MTOR | Phase 2 | Non-Small Cell Lung Cancer; Meningioma; Metastatic Breast Cancer; BRCA1 Mutation Carrier | – |
| AZD5305 PARP inhibitor | PARP1, PARP2 | Phase 1 | Prostate Cancer; Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer; Ovarian Cancer; Breast Cancer … | Nov 2026 |
| AZD9750 AR-PROTAC (proteolysis-targeting chimera) | AR | Phase 1 | Prostate Cancer | Nov 2026 |
| AZD1613 | – | Phase 1 | Healthy; Autosomal Dominant Polycystic Kidney Disease | Nov 2026 |
| AZD0754 CAR T-cell therapy | – | Phase 1 | Metastatic Prostate Cancer | Nov 2026 |
| Oleclumab 5'-nucleotidase inhibitor | NT5E | Phase 1 | Carcinoma, Non-Small-Cell Lung; Metastatic Microsatellite-stable Colorectal Cancer | Nov 2026 |
| Fexagratinib (AZD4547) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 1 | Muscle Invasive Bladder Cancer; Metastatic Breast Cancer | Nov 2026 |
| AZD3974 | – | Phase 1 | Healthy Participants | Dec 2026 |
| AZD4248 | – | Phase 1 | Chronic Kidney Disease | Dec 2026 |
| AZD4117 H5N1 avian influenza vaccine | – | Phase 1 | Influenza A | Dec 2026 |
| AZD5315 H7N9 avian influenza vaccine | – | Phase 1 | Influenza A | Dec 2026 |
| FPI-2053 Bispecific antibody targeting EGFR and cMET | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| [111In]-FPI-2107 Imaging agent (indium-111 conjugated to FPI-2053 bispecific antibody targeting EGFR and cM | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| [225Ac]-FPI-2068 Alpha-emitting radiopharmaceutical (actinium-225) conjugated to bispecific antibody target | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| cediranib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | KIT, PDGFRB, PDGFRA, FLT1, FLT4 | Phase 1 | Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer … | Dec 2026 |
| Casdatifan (AB521) | – | Phase 1 | Advanced Clear Cell Renal Cell Carcinoma | Jan 2027 |
| AZD7760 TRPM3 antagonist | – | Phase 1 | Staphylococcus Aureus; Staphylococcus Aureus Bloodstream Infection | Mar 2027 |
| AZD0543 | – | Phase 1 | Human Metapneumovirus Infection | Mar 2027 |
| AZD4360 anti-CLDN18.2 antibody-drug conjugate | – | Phase 1 | Gastric Cancer | Mar 2027 |
| AZD1705 | – | Phase 1 | Cardiovascular | Apr 2027 |
| AZD1043 | – | Phase 1 | Healthy Participants | Apr 2027 |
| AZD4954 Lipoprotein(a) (Lp[a]) modulator | – | Phase 1 | Healthy Participants | Apr 2027 |
| AZD7789 (sabestomig) anti-PD-1 and anti-TIM-3 bispecific antibody | PDCD1, HAVCR2 | Phase 1 | Carcinoma, Non-Small-Cell Lung; Advanced or Metastatic NSCLC | May 2027 |
| AZD5492 CD8/TCR-based T-cell engaging antibody targeting CD20 | CD20 | Phase 1 | Systemic Lupus Erythematosus; B-cell Malignancies | May 2027 |
| AZD8421 CDK2 inhibitor | CDK2 | Phase 1 | ER+ HER2- Advanced Breast Cancer | Jun 2027 |
| AZD9793 T cell-engaging antibody targeting GPC3 on tumour cells | GPC3 | Phase 1 | Hepatocellular Carcinoma | Jun 2027 |
| Monalizumab (IPH2201) NKG2-A/NKG2-B type II integral membrane protein inhibitor | KLRC1 | Phase 1 | Advanced Solid Tumors | Jul 2027 |
| ALXN2230 | – | Phase 1 | Healthy Adult Participants | Aug 2027 |
| AZD6489 RSV recombinant prefusion F protein virus-like particle (VLP) vaccine | RSV | Phase 1 | RSV Respiratory Syncytial Virus | Aug 2027 |
| AZD0240 Autologous TCR-engineered T cells targeting KRAS G12D mutation (HLA-A*11:01 or HLA-A*11:02 | – | Phase 1 | Non-small Cell Lung Cancer | Aug 2027 |
| NT-112 Autologous TCR-engineered T cells targeting KRAS G12D mutation (HLA-C*08:02 restricted) | – | Phase 1 | Non-small Cell Lung Cancer | Aug 2027 |
| Palacaparib (AZD9574) PARP inhibitor | PARP1, PARP2 | Phase 1 | Breast Cancer; Advanced Solid Malignancies; Metastatic Prostate Cancer | Sep 2027 |
| AZD8359 STEAP2-targeting T cell engager (TCE) | STEAP2 | Phase 1 | Metastatic Prostate Cancer | Nov 2027 |
| AZD4063 Phospholamban (PLN) inhibitor targeting R14del mutation | PLN | Phase 1 | Dilated Cardiomyopathy | Nov 2027 |
| MEDI5752 Bispecific antibody targeting TIGIT and CD155 immune checkpoint | – | Phase 1 | Advanced Renal Cell Carcinoma; Selected Advanced Solid Tumors | Nov 2027 |
| AZD5851 GPC3-directed CAR-T cell therapy | GPRC3 | Phase 1 | Hepatocellular Carcinoma | Dec 2027 |
| AZD4916 | – | Phase 1 | Healthy Participants | Dec 2027 |
| AZD0305 | – | Phase 1 | Multiple Myeloma | Jan 2028 |
| AZD4512 anti-CD22 antibody-drug conjugate | CD22 | Phase 1 | B-cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia (B-ALL) | Jul 2028 |
| AZD9592 | – | Phase 1 | Advanced Solid Tumours | Aug 2028 |
| AZD2962 IRAK4 inhibitor | IRAK4 | Phase 1 | Haematologic Neoplasms | Oct 2028 |
| AZD3470 PRMT5 inhibitor | PRMT5 | Phase 1 | Advanced Solid Tumors That Are MTAP Deficient; Lymphoma | Dec 2028 |
| AZD0516 | – | Phase 1 | Metastatic Prostate Cancer | Jan 2029 |
| AZD3632 MLLT3 protein-protein interaction inhibitor; targets menin-KMT2A interaction in KMT2A-rear | MLLT3 | Phase 1 | Acute Lymphoblastic Leukaemia | Feb 2029 |
| AZD5863 T cell-engaging bi-specific antibody targeting CLDN18.2 and CD3 | CLDN18, CD3E | Phase 1 | Gastric Cancer | Mar 2029 |
| AZD6621 T cell-engaging antibody targeting STEAP2, CD3, and CD8 | STEAP2, CD3, CD8 | Phase 1 | Prostate Cancer | Mar 2029 |
| AZD2275 | – | Phase 1 | Metastatic Castration-Resistant Prostate Cancer | Apr 2029 |
| AZD2284 PSMA-targeted alpha-emitting radiopharmaceutical | – | Phase 1 | Metastatic Castration-Resistant Prostate Cancer | Apr 2029 |
| AZD2287 | – | Phase 1 | Metastatic Castration-Resistant Prostate Cancer | Apr 2029 |
| NT-175 Autologous engineered T cell therapy expressing HLA-A*02:01-restricted TCR targeting TP53 | – | Phase 1 | Non-small Cell Lung Cancer | Jul 2029 |
| AZD6750 CD8-targeted IL-2 immunomodulator | IL2 | Phase 1 | Melanoma | Oct 2029 |
| AZD4956 PARP inhibitor | PARP1, PARP2 | Phase 1 | Solid Tumours | Mar 2030 |
| AZD4045 Allogeneic CAR-T cell therapy targeting BCMA (B cell maturation antigen) | TNFRSF17 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Mar 2031 |
| ALXN2350 AAV9-mediated BAG3 gene therapy | BAG3 | Phase 1 | BAG3 Mutation Associated Dilated Cardiomyopathy | Jan 2032 |
| AZD1390 ATM inhibitor | ATM | Phase 1 | Recurrent Glioblastoma Multiforme; Non Small Cell Lung Cancer; Solid Tumor | – |
| Atezolizumab (MEDI4736) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 1 | Ovarian | – |
| Imaradenant (AZD4635) Adenosine A2a receptor antagonist | ADORA2A | Phase 1 | Carcinoma, Non-Small-Cell Lung | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01167712 | Bevacizumab | Phase 3 | Fallopian Tube Endometrioid Adenocarcinoma | Oncology | Dec 2015 |
| NCT02048813 | Rituximab | Phase 3 | Anemia | Oncology | Oct 2018 |
| NCT01992952 | Capivasertib | Phase 1 | Estrogen Receptor Positive Breast Cancer | Oncology | Mar 2019 |
| NCT03010436 | Benralizumab | Phase 2 | Asthma | Respiratory | Jul 2019 |
| NCT03330847 | Adavosertib (AZD1775) | Phase 2 | Metastatic Triple Negative Breast Cancer | Oncology | Nov 2020 |
| NCT03330847 | ceralasertib | Phase 2 | Metastatic Triple Negative Breast Cancer | Oncology | Nov 2020 |
| NCT02142803 | Bevacizumab | Phase 1 | Adult Glioblastoma | Oncology | Dec 2020 |
| NCT03775486 | Durvalumab (MEDI4736) | Phase 2 | Non-small Cell Lung Cancer NSCLC | Oncology | Jan 2021 |
| NCT03775486 | Olaparib | Phase 2 | Non-small Cell Lung Cancer NSCLC | Oncology | Jan 2021 |
| NCT00492050 | Rituximab | Phase 2 | Waldenstrom's Macroglobulinemia | Oncology | Feb 2021 |
| NCT03381274 | Oleclumab | Phase 1 | Carcinoma, Non-Small-Cell Lung | Oncology | May 2021 |
| NCT03381274 | Imaradenant (AZD4635) | Phase 1 | Carcinoma, Non-Small-Cell Lung | Oncology | May 2021 |
| NCT02734004 | Olaparib | Phase 1 | Ovarian | Oncology | Sep 2021 |
| NCT02734004 | Atezolizumab (MEDI4736) | Phase 1 | Ovarian | Oncology | Sep 2021 |
| NCT03653052 | Durvalumab (MEDI4736) | Phase 2 | Oesophageal Cancer | Oncology | Nov 2021 |
| NCT04460248 | Rituximab | Phase 2 | Diffuse Large B Cell Lymphoma | Oncology | Feb 2022 |
| NCT03641755 | Olaparib | Phase 1 | Breast Cancer | Oncology | Apr 2022 |
| NCT04590963 | Monalizumab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | Oncology | May 2022 |
| NCT03071874 | Vistusertib | Phase 2 | Meningioma | Oncology | Jun 2022 |
| NCT03704480 | Durvalumab (MEDI4736) | Phase 2 | Advanced Biliary Tract Carcinoma | Oncology | Jul 2022 |
| NCT03704480 | Tremelimumab | Phase 2 | Advanced Biliary Tract Carcinoma | Oncology | Jul 2022 |
| NCT04590235 | Selumetinib | Phase 1 | Neurofibromatosis 1 | Oncology | Aug 2022 |
| NCT03003962 | Durvalumab (MEDI4736) | Phase 3 | Non Small Cell Lung Carcinoma NSCLC | Oncology | Oct 2022 |
| NCT02299999 | Fexagratinib (AZD4547) | Phase 2 | Metastatic Breast Cancer | Oncology | Dec 2022 |
| NCT03308396 | Durvalumab (MEDI4736) | Phase 1 | Advanced Kidney Cancer | Oncology | Dec 2022 |
| NCT02299999 | Capivasertib | Phase 2 | Metastatic Breast Cancer | Oncology | Dec 2022 |
| NCT02299999 | Vistusertib | Phase 2 | Metastatic Breast Cancer | Oncology | Dec 2022 |
| NCT03932331 | Acalabrutinib | Phase 1 | Phase I: Relapsed or Refractory B-cell Malignancies | Oncology | Dec 2022 |
| NCT03795311 | Bevacizumab | Phase 1 | Colorectal Cancer | Oncology | Jan 2023 |
| NCT04639219 | Trastuzumab deruxtecan | Phase 2 | Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast | Oncology | Jan 2023 |
| NCT03161223 | Durvalumab (MEDI4736) | Phase 1 | Lymphoma, T-Cell | Oncology | Feb 2023 |
| NCT04305496 | Capivasertib | Phase 3 | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Oncology | May 2023 |
| NCT03819465 | Durvalumab (MEDI4736) | Phase 1 | Metastatic Non-Small Cell Lung Cancer (NSCLC) | Oncology | May 2023 |
| NCT03819465 | Danvatirsen | Phase 1 | Metastatic Non-Small Cell Lung Cancer (NSCLC) | Oncology | May 2023 |
| NCT03819465 | Oleclumab | Phase 1 | Metastatic Non-Small Cell Lung Cancer (NSCLC) | Oncology | May 2023 |
| NCT03819465 | Volrustomig (MEDI5752) | Phase 1 | Metastatic Non-Small Cell Lung Cancer (NSCLC) | Oncology | May 2023 |
| NCT04348045 | Durvalumab (MEDI4736) | Phase 2 | Metastatic Pancreatic Adenocarcinoma | Oncology | Jun 2023 |
| NCT04348045 | Olaparib | Phase 2 | Metastatic Pancreatic Adenocarcinoma | Oncology | Jun 2023 |
| NCT04348045 | Selumetinib | Phase 2 | Metastatic Pancreatic Adenocarcinoma | Oncology | Jun 2023 |
| NCT04308174 | Durvalumab (MEDI4736) | Phase 2 | Biliary Tract Neoplasms | Oncology | Jun 2023 |
| NCT03778957 | Durvalumab (MEDI4736) | Phase 3 | Hepatocellular Carcinoma | Oncology | Sep 2023 |
| NCT03778957 | Bevacizumab | Phase 3 | Hepatocellular Carcinoma | Oncology | Sep 2023 |
| NCT04940546 | Bevacizumab | Phase 1 | Colorectal Cancer Metastatic | Oncology | Oct 2023 |
| NCT03161353 | Trastuzumab deruxtecan | Phase 2 | Breast Cancer | Oncology | Nov 2023 |
| NCT03828227 | Bevacizumab | Phase 3 | Elderly Patients | Oncology | Nov 2023 |
| NCT03688451 | Rituximab | Phase 2 | Non Hodgkin Lymphoma | Oncology | Dec 2023 |
| NCT03703297 | Durvalumab (MEDI4736) | Phase 3 | Small Cell Lung Cancer | Oncology | Jan 2024 |
| NCT03703297 | Tremelimumab | Phase 3 | Small Cell Lung Cancer | Oncology | Jan 2024 |
| NCT03482102 | Durvalumab (MEDI4736) | Phase 2 | Hepatocellular Carcinoma | Oncology | Feb 2024 |
| NCT03482102 | Tremelimumab | Phase 2 | Hepatocellular Carcinoma | Oncology | Feb 2024 |
| NCT04494425 | Trastuzumab deruxtecan | Phase 3 | Advanced or Metastatic Breast Cancer | Oncology | Mar 2024 |
| NCT05061134 | Durvalumab (MEDI4736) | Phase 2 | Melanoma | Oncology | Apr 2024 |
| NCT05061134 | ceralasertib | Phase 2 | Melanoma | Oncology | Apr 2024 |
| NCT04333823 | Dapagliflozin | Phase 3 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | May 2024 |
| NCT04563338 | Bevacizumab | Phase 2 | Hepatocellular Carcinoma | Oncology | Jun 2024 |
| NCT06094140 | Durvalumab (MEDI4736) | Phase 2 | Pancreatic Cancer | Oncology | Jun 2024 |
| NCT03813394 | Bevacizumab | Phase 1 | Locally Recurrent Cancer | Oncology | Jul 2024 |
| NCT05601973 | Bevacizumab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Aug 2024 |
| NCT05751343 | Bevacizumab | Phase 2 | Hepatocellular Carcinoma | Oncology | Aug 2024 |
| NCT07014280 | Bevacizumab | Phase 4 | Keloids | Immunology | Sep 2024 |
The 60 nearest readouts of 1690 trials; the rest in the app.
Cash and short-term investments of $5.7bn on 2025-12-31; operating cash flow positive
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.